摘要
目的探讨尼可地尔联合芪苈强心胶囊治疗冠状动脉粥样硬化性心脏病(简称冠心病)合并心力衰竭的临床效果。方法随机选取2024年3月—2025年3月乌鲁木齐市第一人民医院分院收治的180例冠心病合并心力衰竭患者为研究对象。根据治疗方式的不同分为两组,即对照组(n=90)和观察组(n=90)。对照组患者给予尼可地尔治疗,观察组在对照组的基础上联合芪苈强心胶囊治疗,两组均治疗12周。比较治疗前后两组患者的心功能指标、心肌损伤指标、生活质量。治疗12周后进行疗效判定,并统计不良反应发生情况。结果治疗后,观察组左室射血分数(65.37±1.12)%高于对照组的(52.56±1.75)%,左室收缩末期内径(44.61±3.35)mm与左室舒张末期内径(36.36±3.71)mm均低于对照组的(53.49±4.61)mm、(43.12±4.33)mm,差异均有统计学意义(t=58.490,14.783,11.247;P均<0.05);治疗后,观察组脑钠肽(180.32±10.33)ng/L、肌酸激酶同工酶(51.33±6.12)IU/L、肌钙蛋白I(0.28±0.11)μg/L均低于对照组的(255.63±12.34)ng/L、(86.33±6.32)IU/L、(0.52±0.13)μg/L,差异均有统计学意义(t=44.395,37.742,13.370;P均<0.05);治疗后,观察组生活质量评分为(62.13±5.32)分,低于对照组(71.33±6.37)分,差异有统计学意义(t=10.516,P<0.05);两组总有效率比较,差异有统计学意义(P<0.05)。但两组治疗相关不良反应总发生率比较,差异无统计学意义(P>0.05)。结论尼可地尔治疗冠心病合并心力衰竭基础上配合实施芪苈强心胶囊治疗可获得更好的临床效果。
Objective To investigate the clinical effect of nicorandil combined with Qili Qiangxin capsule in the treatment of coronary atherosclerotic heart disease(coronary heart disease)complicated with heart failure.Methods From March 2024 to March 2025,180 patients with coronary heart disease and heart failure admitted to the Urumqi First People's Hospital branch were randomly selected as the subjects.According to the different treatment methods,they were divided into two groups,namely the control group(n=90)and the observation group(n=90).The control group was treated with nicorandil,and the observation group was treated with Qili Qiangxin capsule on the basis of the control group.Both groups were treated for 12 weeks.The cardiac function indexes,myocardial injury indexes and quality of life scores of the two groups before and after treatment were compared.After 12 weeks of treatment,the efficacy was determined and the occurrence of adverse reactions was counted.Results After treatment,the observation group had higher left ventricular ejection fraction as(65.37±1.12)%than(52.56±1.75)%in the control group,and smaller left ventricular end-systolic diameter as(44.61±3.35)mm and left ventricular end-diastolic diameter as(36.36±3.71)mm than(53.49±4.61)mm and(43.12±4.33)mm in the control group.Their differences were statistically significant(t=58.490,14.783,11.247;all P<0.05).After treatment,the observation group had lower brain natriuretic peptide as(180.32±10.33)ng/L,creatine kinase isoenzyme as(51.33±6.12)IU/L and cardiac troponin I as(0.28±0.11)μg/L than(255.63±12.34)ng/L,(86.33±6.3)IU/L and(0.52±0.13)μg/L in the control group,and the differences were statistically significant(t=44.395,37.742,13.370;all P<0.05).After treatment,the quality of life score of the observation group was(62.13±5.32),which was lower than(71.33±6.37)of the control group,and the difference was statistically significant(t=10.516,P<0.05).Comparison of total effective rate between the two groups,the difference was statistically significant(P<0.05).However,there was no significant difference in the total incidence of treatment-related adverse reactions between the two groups(P>0.05).Conclusion Nicorandil combined with Qili Qiangxin capsule in the treatment of coronary heart disease complicated with heart failure can achieve better clinical effect.
作者
刘玉
马晨璐
王芳
周云
LIU Yu;MA Chenlu;WANG Fang;ZHOU Yun(Department of Internal Medicine,Section Two,Urumqi First People's Hospital Branch,Urumqi 830000,Xinjiang Uygur Autonomous Region,China)
出处
《系统医学》
2025年第24期115-118,123,共5页
Systems Medicine
